These data suggested that IL-2cxCD25 activated CD8+ T cells preferentially in the tumor due to their CD25 upregulation following RT of the tumor, whereas IL-2cxCD25 stimulated CD8+ T cells in secondary lymphoid organs, i.e., extratumorally. This evidence concerns the gene IL2RA and neoplasm.